
ESOCAP APPOINTS JACQUES GONELLA TO ITS BOARD OF DIRECTORS

Basel, Switzerland, June 9, 2020

EsoCap has announced that Dr Jacques Gonella has been appointed to the Company's Board of Directors.

"I am delighted to welcome Jacques Gonella to the EsoCap Board," said Dr Werner Tschollar, Chairman of the Board of EsoCap. "Jacques will add significant value as an EsoCap Board Member, drawing on 30 years of experience in drug delivery, industrial development and transaction management. His appointment reflects our commitment to ensuring that we have a broad mix of skills and perspectives on the EsoCap Board. We look forward to benefiting from his expertise."

Dr Jacques Gonella served on the Board of Directors of NASDAQ-listed company Antares Pharma Inc. from 2001 to 2019, and served as Chairman of the Board of Directors from 2001 to 2008.

Dr Jacques Gonella founded Permatec (a Swiss company which merged with Medi-Ject, Inc. to form Antares Pharma, Inc.) and had served as Chairman of the Board of Directors of Permatec from its founding in June 1997. Prior to founding Permatec, Dr Gonella founded JAGO Pharma AG in 1983 and served as its President and Chief Executive Officer until its acquisition in 1996 by SkyePharma, PLC, a United Kingdom company listed on the London Stock Exchange and quoted on NASDAQ.

Prior to founding JAGO, Dr Gonella occupied various positions with F. Hoffmann-La Roche Ltd. and Pfizer Inc.

He has also served as a member of the Board of Directors of Protherics PLC, London and he serves on the Board of Directors of several private companies. He is a private investor and



EsoCap

is proprietor of NobleHouse Consulting Ltd., Hong Kong.

Dr Gonella holds a doctorate in analytical chemistry from the Polytechnic Institute of Lausanne, Switzerland.

"EsoCap is an exciting company," said Dr Jacques Gonella, "with a highly innovative technology to build upon, to deliver considerable value in the biopharmaceutical industry. I look forward to contributing, as a member of the Board of Directors, to EsoCap's future."

Consistent with the leadership transition plan within the EsoCap Board, Caspar Graf von Moy did not seek re-election to EsoCap's Board at the General Assembly on June 9, 2020. Isabelle Racamier, EsoCap CEO said, "I want to thank Caspar Graf von Moy for his contributions during his three years on the EsoCap Board and wish him success in his future endeavours."

About EsoCap

EsoCap AG is a Swiss privately funded company based in Basel, Switzerland.

EsoCap's vision is to improve the lives of patients with serious diseases through the development of a unique topical drug delivery platform for diseases of the upper gastrointestinal tract.

Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve due to ultra-short transit times with less than two seconds from the mouth to the stomach.

EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract.

For more information, please visit

www.esocapbiotech.com.



EsoCap

Contact:

Isabelle Racamier, CEO

EsoCap AG
Malzgasse 9
4052 Basel
Switzerland

isabelle.racamier@esocapbiotech.com